Brief: Calidi Biotherapeutics - On July 24, Eliminates President, Medical And Scientific Affairs Position - SEC Filing
25/07/2025 22:07
July 25 (Reuters) - Calidi Biotherapeutics Inc CLDI.A: CALIDI BIOTHERAPEUTICS INC - ON JULY 24, ELIMINATES PRESIDENT, MEDICAL AND SCIENTIFIC AFFAIRS POSITION - SEC FILING Source text: [ID:n0001641172-25-021039] Further company coverage: CLDI.A ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Calidi Biotherapeutics
See all newsBrief: Calidi Biotherapeutics Announces Strategic Partnership With Transferai
Brief: Calidi Biotherapeutics Announces Partnership With Avance Clinical To Facilitate Australian Regulatory Approval
Brief: Calidi Biotherapeutics Announces Pricing Of $5.2 Million Underwritten Public Offering
Brief: Calidi Biotherapeutics Eliminates Chief Legal Officer Position - SEC Filing
Brief: Calidi Biotherapeutics Receives FDA Fast Track Designation For Cld-201 (Supernova), A First-In-Class Stem-Cell Loaded Viral Therapy For The Treatment Of Patients With Soft Tissue Sarcoma